

Jeffrey Wagner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1620677/publications.pdf>

Version: 2024-02-01

45
papers

3,296
citations

185998

28
h-index

233125

45
g-index

45
all docs

45
docs citations

45
times ranked

2636
citing authors

#	ARTICLE	IF	CITATIONS
1	Epidemiologic Study of Cystic Fibrosis: 25 years of observational research. <i>Pediatric Pulmonology</i> , 2021, 56, 823-836.	1.0	11
2	Triglyceride Levels and Residual Risk of Atherosclerotic Cardiovascular Disease Events and Death in Adults Receiving Statin Therapy for Primary or Secondary Prevention: Insights From the KP REACH Study. <i>Journal of the American Heart Association</i> , 2021, 10, e020377.	1.6	12
3	Lung function changes before and after pulmonary exacerbation antimicrobial treatment in cystic fibrosis. <i>Pediatric Pulmonology</i> , 2020, 55, 828-834.	1.0	21
4	VT or Not VT?. <i>Circulation</i> , 2020, 142, 605-607.	1.6	2
5	Pulmonary exacerbations and acute declines in lung function in patients with cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2018, 17, 496-502.	0.3	15
6	Frequency and level of evidence used in recommendations by the National Comprehensive Cancer Network guidelines beyond approvals of the US Food and Drug Administration: retrospective observational study. <i>BMJ: British Medical Journal</i> , 2018, 360, k668.	2.4	28
7	Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D-CFTR mutation treated with ivacaftor. <i>Journal of Cystic Fibrosis</i> , 2018, 17, 83-88.	0.3	36
8	Frequency and costs of pulmonary exacerbations in patients with cystic fibrosis in the United States. <i>Current Medical Research and Opinion</i> , 2017, 33, 667-674.	0.9	32
9	BMI fails to identify poor nutritional status in stunted children with CF. <i>Journal of Cystic Fibrosis</i> , 2017, 16, 158-160.	0.3	20
10	Relationship of Antibiotic Treatment to Recovery after Acute FEV ₁ Decline in Children with Cystic Fibrosis. <i>Annals of the American Thoracic Society</i> , 2017, 14, 937-942.	1.5	35
11	Comparison of FEV ₁ reference equations for evaluating a cystic fibrosis therapeutic intervention. <i>Pediatric Pulmonology</i> , 2017, 52, 1013-1019.	1.0	6
12	Strengthening care teams to improve adherence in cystic fibrosis: a qualitative practice assessment and quality improvement initiative. <i>Patient Preference and Adherence</i> , 2017, Volume 11, 761-767.	0.8	9
13	Improving performance in the detection and management of cystic fibrosis-related diabetes in the Mountain West Cystic Fibrosis Consortium. <i>BMJ Open Diabetes Research and Care</i> , 2016, 4, e000183.	1.2	7
14	Healthcare resource utilization associated with ivacaftor use in patients with cystic fibrosis. <i>Journal of Medical Economics</i> , 2016, 19, 845-851.	1.0	13
15	Forced Expiratory Volume in 1 Second Variability Helps Identify Patients with Cystic Fibrosis at Risk of Greater Loss of Lung Function. <i>Journal of Pediatrics</i> , 2016, 169, 116-121.e2.	0.9	44
16	Pulmonary function outcomes for assessing cystic fibrosis care. <i>Journal of Cystic Fibrosis</i> , 2015, 14, 376-383.	0.3	16
17	Liver Involvement in the Hispanic Population of North America With Cystic Fibrosis. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2014, 59, 476-479.	0.9	7
18	Clinical use of tobramycin inhalation solution (TOBIÂ®) shows sustained improvement in FEV ₁ in cystic fibrosis. <i>Pediatric Pulmonology</i> , 2014, 49, 529-536.	1.0	16

#	ARTICLE	IF	CITATIONS
19	Probability of Treatment Following Acute Decline in Lung Function in Children with Cystic Fibrosis is Related to Baseline Pulmonary Function. <i>Journal of Pediatrics</i> , 2013, 163, 1152-1157.e2.	0.9	36
20	Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis. <i>Pediatric Pulmonology</i> , 2013, 48, 666-673.	1.0	99
21	Pulmonary exacerbations in cystic fibrosis: Young children with characteristic signs and symptoms. <i>Pediatric Pulmonology</i> , 2013, 48, 649-657.	1.0	44
22	Newborn screening for cystic fibrosis. <i>Current Opinion in Pediatrics</i> , 2012, 24, 329-335.	1.0	69
23	Risk factors for rate of decline in FEV1 in adults with cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2012, 11, 405-411.	0.3	96
24	Lung function decline from adolescence to young adulthood in cystic fibrosis. <i>Pediatric Pulmonology</i> , 2012, 47, 135-143.	1.0	99
25	Socioeconomic Status and the Likelihood of Antibiotic Treatment for Signs and Symptoms of Pulmonary Exacerbation in Children with Cystic Fibrosis. <i>Journal of Pediatrics</i> , 2011, 159, 819-824.e1.	0.9	36
26	Longitudinal assessment of health-related quality of life in an observational cohort of patients with cystic fibrosis. <i>Pediatric Pulmonology</i> , 2011, 46, 36-44.	1.0	85
27	Clinical use of dornase alfa is associated with a slower rate of FEV ₁ decline in cystic fibrosis. <i>Pediatric Pulmonology</i> , 2011, 46, 545-553.	1.0	76
28	Impact of Socioeconomic Status, Race, and Ethnicity on Quality of Life in Patients With Cystic Fibrosis in the United States. <i>Chest</i> , 2010, 137, 642-650.	0.4	110
29	Pulmonary outcome prediction (POP) tools for cystic fibrosis patients. <i>Pediatric Pulmonology</i> , 2010, 45, 1156-1166.	1.0	39
30	Trends in the use of routine therapies in cystic fibrosis: 1995-2005. <i>Pediatric Pulmonology</i> , 2010, 45, 1167-1172.	1.0	58
31	Year-to-year changes in lung function in individuals with cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2010, 9, 250-256.	0.3	98
32	Association of Socioeconomic Status with the Use of Chronic Therapies and Healthcare Utilization in Children with Cystic Fibrosis. <i>Journal of Pediatrics</i> , 2009, 155, 634-639.e4.	0.9	92
33	Trends in the clinical characteristics of the U.S. cystic fibrosis patient population from 1995 to 2005. <i>Pediatric Pulmonology</i> , 2008, 43, 739-744.	1.0	21
34	Shifting patterns of inhaled antibiotic use in cystic fibrosis. <i>Pediatric Pulmonology</i> , 2008, 43, 874-881.	1.0	56
35	The impact of incident methicillin resistant <i>Staphylococcus aureus</i> detection on pulmonary function in cystic fibrosis. <i>Pediatric Pulmonology</i> , 2008, 43, 1117-1123.	1.0	77
36	Relationship between Inhaled Corticosteroid Therapy and Rate of Lung Function Decline in Children with Cystic Fibrosis. <i>Journal of Pediatrics</i> , 2008, 153, 746-751.e2.	0.9	72

#	ARTICLE	IF	CITATIONS
37	Infant Care Patterns at Epidemiologic Study of Cystic Fibrosis Sites That Achieve Superior Childhood Lung Function. <i>Pediatrics</i> , 2007, 119, e531-e537.	1.0	60
38	Presence of methicillin resistant <i>Staphylococcus aureus</i> in respiratory cultures from cystic fibrosis patients is associated with lower lung function. <i>Pediatric Pulmonology</i> , 2007, 42, 513-518.	1.0	139
39	Risk Factors For Rate of Decline in Forced Expiratory Volume in One Second in Children and Adolescents with Cystic Fibrosis. <i>Journal of Pediatrics</i> , 2007, 151, 134-139.e1.	0.9	384
40	Impact of Pregnancy on Women With Cystic Fibrosis. <i>Chest</i> , 2006, 129, 706-711.	0.4	165
41	Update on newborn screening for cystic fibrosis. <i>Current Opinion in Pulmonary Medicine</i> , 2004, 10, 500-504.	1.2	10
42	Growth and nutritional indexes in early life predict pulmonary function in cystic fibrosis. <i>Journal of Pediatrics</i> , 2003, 142, 624-630.	0.9	355
43	Cystic fibrosis: current trends in respiratory care. <i>Respiratory Care</i> , 2003, 48, 234-45; discussion 246-7.	0.8	31
44	A debate on why my state (province) should or should not conduct newborn screening for cystic fibrosis (14th Annual North American Cystic Fibrosis Conference). <i>Pediatric Pulmonology</i> , 2001, 32, 385-396.	1.0	14
45	Early Pulmonary Inflammation in Infants with Cystic Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1995, 151, 1075-1082.	2.5	545